文献速递淋巴瘤白血病

Akt抑制剂MK-2206联合苯达莫司汀和利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病:N1087 Alliance研究结果

Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
PubMed 文献 · Am J Hematol · 2017-06-01

这项I/II期研究评估Akt抑制剂MK-2206联合苯达莫司汀和利妥昔单抗(BR)治疗复发或难治性慢性淋巴细胞白血病(CLL)的安全性和疗效。共13例患者接受最多6周期治疗,MK-2206最大耐受剂量为90 mg口服每周一次。总缓解率92%,中位无进展生存期16个月,中位无治疗生存期24个月,最常见3/4级不良事件为中性粒细胞减少(46%)和发热性中性粒细胞减少(23%)。

要点

  • MK-2206联合BR的最大耐受剂量为90 mg口服每周一次。
  • 13例复发/难治CLL患者总缓解率92%,5例(38%)达完全缓解或伴不完全计数恢复的完全缓解。
  • 中位无进展生存期16个月,中位无治疗生存期24个月。

核心结论

  • 该联合方案的疗效和耐受性表明,Akt抑制联合化学免疫治疗是CLL中有前景的新型治疗组合,值得进一步前瞻性临床试验。

研究设计与样本

  • I/II期研究,采用标准I期3+3设计确定MK-2206联合BR在复发CLL中的最大耐受剂量。
  • 单药MK-2206每周给药于第1周期BR前一周开始,第2-6周期与BR同时给予。
  • II期采用MK-2206的最大耐受剂量联合BR评估安全性和疗效,13例复发/难治CLL患者接受最多6周期治疗。

主要发现

  • MK-2206的最大耐受剂量为90 mg口服每周一次。
  • 最常见3/4级不良事件为中性粒细胞减少(46%)、发热性中性粒细胞减少(23%)、皮疹(15%)、腹泻(15%)和血小板减少(15%)。
  • 总缓解率为92%,中位无进展生存期16个月,中位无治疗生存期24个月。
  • 5例患者(38%)达到完全缓解或伴不完全计数恢复的完全缓解,其中2例微小残留病阴性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard phase I design was used with cohorts of three plus three patients to determine the maximum tolerated dose (MTD) of MK-2206 in combination with BR in relapsed CLL. Single-agent MK-2206 (weekly dosed) was administered one-week in advance before BR on cycle 1 and subsequently was given with BR at the same time for cycle 2-6. Phase II employed the MTD of MK-2206 with BR to evaluate safety and efficacy of this study combination. Thirteen relapsed/refractory CLL were treated for maximal 6-cycle of therapy. The maximum tolerated dose of MK-2206 was 90 mg by mouth once weekly. The most common grade 3/4 adverse events were neutropenia (46%), febrile neutropenia (23%), rash (15%), diarrhea (15%), and thrombocytopenia (15%). Overall response rate was 92% with a median progression free survival and treatment free survival of 16 and 24 months, respectively. Five patients (38%) achieved complete remission or complete remission with incomplete count recovery, two of whom were MRD negative. The efficacy and tolerability of this combination indicates that Akt inhibition combined with chemoimmunotherapy is a promising novel treatment combination in CLL and deserves further prospective clinical trial.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Larsen JT, Shanafelt TD, Leis JF, et al. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. Am J Hematol. 2017. PMID: 28402581. doi:10.1002/ajh.24762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。